160 related articles for article (PubMed ID: 30957954)
1. The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders.
Troxler T; Feuerbach D; Zhang X; Yang CR; Lagu B; Perrone M; Wang TL; Briner K; Bock MG; Auberson YP
ChemMedChem; 2019 Jul; 14(13):1238-1247. PubMed ID: 30957954
[TBL] [Abstract][Full Text] [Related]
2. Ergoline-derived inverse agonists of the human h3 receptor for the treatment of narcolepsy.
Auberson YP; Troxler T; Zhang X; Yang CR; Fendt M; Feuerbach D; Liu YC; Lagu B; Lerchner A; Perrone M; Lei L; Zhang C; Wang C; Wang TL; Bock MG
ChemMedChem; 2014 Aug; 9(8):1683-96. PubMed ID: 24850792
[TBL] [Abstract][Full Text] [Related]
3. Histamine H(3) receptor (H(3)R) antagonists and inverse agonists in the treatment of sleep disorders.
Broderick M; Masri T
Curr Pharm Des; 2011; 17(15):1426-9. PubMed ID: 21476958
[TBL] [Abstract][Full Text] [Related]
4. 3-(1'-Cyclobutylspiro[4H-1,3-benzodioxine-2,4'-piperidine]-6-yl)-5,5-dimethyl-1,4-dihydropyridazin-6-one (CEP-32215), a new wake-promoting histamine H3 antagonist/inverse agonist.
Hudkins RL; Gruner JA; Raddatz R; Mathiasen JR; Aimone LD; Marino MJ; Bacon ER; Williams M; Ator MA
Neuropharmacology; 2016 Jul; 106():37-45. PubMed ID: 26400408
[TBL] [Abstract][Full Text] [Related]
5. 1-[2-(1-Cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one: a Histamine H
Shinde AK; Badange RK; Reballi V; Achanta PK; Bojja K; Manchineella S; Rao Muddana N; Subramanian R; Choudary Palacharla R; Benade V; Jayarajan P; Thentu JB; Lingavarapu BB; Yarra S; Kagita N; Rao Doguparthi M; Mohammed AR; Nirogi R
ChemMedChem; 2022 Feb; 17(3):e202100583. PubMed ID: 34761873
[TBL] [Abstract][Full Text] [Related]
6. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18.
Hamill TG; Sato N; Jitsuoka M; Tokita S; Sanabria S; Eng W; Ryan C; Krause S; Takenaga N; Patel S; Zeng Z; Williams D; Sur C; Hargreaves R; Burns HD
Synapse; 2009 Dec; 63(12):1122-32. PubMed ID: 19670309
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H
Nirogi R; Shinde A; Mohammed AR; Badange RK; Reballi V; Bandyala TR; Saraf SK; Bojja K; Manchineella S; Achanta PK; Kandukuri KK; Subramanian R; Benade V; Palacharla RC; Jayarajan P; Pandey S; Jasti V
J Med Chem; 2019 Feb; 62(3):1203-1217. PubMed ID: 30629436
[TBL] [Abstract][Full Text] [Related]
8. The discovery of the benzazepine class of histamine H3 receptor antagonists.
Wilson DM; Apps J; Bailey N; Bamford MJ; Beresford IJ; Briggs MA; Calver AR; Crook B; Davis RP; Davis S; Dean DK; Harris L; Heightman TD; Panchal T; Parr CA; Quashie N; Steadman JG; Schogger J; Sehmi SS; Stean TO; Takle AK; Trail BK; White T; Witherington J; Worby A; Medhurst AD
Bioorg Med Chem Lett; 2013 Dec; 23(24):6897-901. PubMed ID: 24161834
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel lead in the group of N-substituted piperazine ether derivatives with potential histamine H3 receptor activity.
Kuder KJ; Stachnik M; Schunack W; Szymańska E; Kieć-Kononowicz K
Med Chem; 2014; 10(6):588-99. PubMed ID: 24047214
[TBL] [Abstract][Full Text] [Related]
10. Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.
Hudkins RL; Josef KA; Becknell NC; Aimone LD; Lyons JA; Mathiasen JR; Gruner JA; Raddatz R
Bioorg Med Chem Lett; 2014 Mar; 24(5):1303-6. PubMed ID: 24513042
[TBL] [Abstract][Full Text] [Related]
11. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
[TBL] [Abstract][Full Text] [Related]
12. Phenyl-oxazoles, a new family of inverse agonists at the H(3) histamine receptor.
Denonne F; Atienzar F; Célanire S; Christophe B; Delannois F; Delaunoy C; Delporte ML; Durieu V; Gillard M; Lallemand B; Lamberty Y; Lorent G; Vanbellinghen A; Van Houtvin N; Verbois V; Provins L
ChemMedChem; 2010 Feb; 5(2):206-12. PubMed ID: 20043314
[No Abstract] [Full Text] [Related]
13. Discovery of Novel Steroid-Based Histamine H
Ledneczki I; Tapolcsányi P; Gábor E; Éles J; Barabás J; Béni Z; Varga B; Balázs O; Román V; Fodor L; Szikra J; Vastag M; Lévay G; Schmidt É; Lendvai B; Greiner I; Kiss B; Némethy Z; Mahó S
J Med Chem; 2024 Mar; 67(5):3643-3667. PubMed ID: 38393759
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.
Richter HG; Freichel C; Huwyler J; Nakagawa T; Nettekoven M; Plancher JM; Raab S; Roche O; Schuler F; Taylor S; Ullmer C; Wiegand R
Bioorg Med Chem Lett; 2010 Oct; 20(19):5713-7. PubMed ID: 20801030
[TBL] [Abstract][Full Text] [Related]
15. Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.
Wilson DM; Apps J; Bailey N; Bamford MJ; Beresford IJ; Brackenborough K; Briggs MA; Brough S; Calver AR; Crook B; Davis RK; Davis RP; Davis S; Dean DK; Harris L; Heslop T; Holland V; Jeffrey P; Panchal TA; Parr CA; Quashie N; Schogger J; Sehmi SS; Stean TO; Steadman JG; Trail B; Wald J; Worby A; Takle AK; Witherington J; Medhurst AD
Bioorg Med Chem Lett; 2013 Dec; 23(24):6890-6. PubMed ID: 24269482
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic characterization of S 38093, a novel inverse agonist at histamine H3 receptors.
Sors A; Panayi F; Bert L; Favale D; Nosjean O; Audinot V; Arrang JM; Buisson B; Steidl E; Delbos JM; Huhtala T; Kontkanen O; Chollet AM; Casara P; Lestage P
Eur J Pharmacol; 2017 May; 803():11-23. PubMed ID: 28336400
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists.
Josef KA; Aimone LD; Lyons J; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jun; 22(12):4198-202. PubMed ID: 22617490
[TBL] [Abstract][Full Text] [Related]
18. Covalent Inhibition of the Histamine H
Wágner G; Mocking TAM; Kooistra AJ; Slynko I; Ábrányi-Balogh P; Keserű GM; Wijtmans M; Vischer HF; de Esch IJP; Leurs R
Molecules; 2019 Dec; 24(24):. PubMed ID: 31835873
[TBL] [Abstract][Full Text] [Related]
19. Use of novel, non-imidazole inverse agonist radioligands to define histamine H3 receptor pharmacology.
Esbenshade TA; Yao BB; Witte DG; Carr TL; Sharma R; Baranowski JL; Krueger KM; Miller TR; Surber BW; Faghih R; Hancock AA
Inflamm Res; 2005 Apr; 54 Suppl 1():S46-7. PubMed ID: 15928830
[No Abstract] [Full Text] [Related]
20. Histamine H3 receptor as a drug discovery target.
Berlin M; Boyce CW; Ruiz Mde L
J Med Chem; 2011 Jan; 54(1):26-53. PubMed ID: 21062081
[No Abstract] [Full Text] [Related]
[Next] [New Search]
